Targeting eosinophils in allergy, inflammation and beyond

Fulkerson, Patricia C.; Rothenberg, Marc E.

doi:10.1038/nrd3838

Cited by 419 publications

(365 citation statements)

References 167 publications

(181 reference statements)

Supporting

Mentioning

346

Contrasting

Unclassified

Order By: Relevance

“…90,91 Among these, the humanized monoclonal anti-IL-5 antibody, mepolizumab, has been the best studied in HES. After promising results in pilot studies, a double-blind, placebo-controlled trial in 85 PDGFRAnegative patients demonstrated that monthly mepolizumab was safe and effective as a steroid-sparing agent in HES, including L-HES.…”

Section: Novel Therapies and Clinical Trialsmentioning

confidence: 99%

How I treat hypereosinophilic syndromes

Klion

2015

Blood

208

126

View full text Add to dashboard Cite

Hypereosinophilic syndromes (HESs) are a group of rare disorders characterized by peripheral blood eosinophilia of 1.5 × 109/L or higher and evidence of end organ manifestations attributable to the eosinophilia and not otherwise explained in the clinical setting. HESs are pleomorphic in clinical presentation and can be idiopathic or associated with a variety of underlying conditions, including allergic, rheumatologic, infectious, and neoplastic disorders. Moreover, the etiology of the eosinophilia in HESs can be primary (myeloid), secondary (lymphocyte-driven), or unknown. Although corticosteroids remain the first-line therapy for most forms of HESs, the availability of an increasing number of novel therapeutic agents, including tyrosine kinase inhibitors and monoclonal antibodies, has necessarily altered the approach to treatment of HESs. This review presents an updated treatment-based approach to the classification of patients with presumed HES and discusses the roles of conventional and novel agents in the management of these patients.

show abstract

Section: Novel Therapies and Clinical Trialsmentioning

confidence: 99%

How I treat hypereosinophilic syndromes

Klion

2015

Blood

208

126

View full text Add to dashboard Cite

show abstract

“…The recruitment of eosinophils is related to the release of cytokines, chemokines and others products such as IL-3, IL-4, IL-5, IL-13, CCL11, CCL24, CCL26, TNFα, integrins, and histamine, released from different cells involved in the disorders (see Figure 1) [2]. Basophils may be recruited to sites of inflammation especially during immune responses against allergens and contribute to hypersensitivity reactions.…”

Section: Introductionmentioning

confidence: 99%

The role of eosinophils and basophils in allergic diseases considering genetic findings

Nadif

Zerimech²,

Matran³

2013

Current Opinion in Allergy &Amp; Clinical Immunology

View full text Add to dashboard Cite

2 Purpose of reviewBasophils and eosinophils respectively represent less than 1 and 5% of white blood cells respectively. Their role in asthma and allergic inflammation remains incompletely defined.The present review addresses recent advances regarding the role of these two cell populations in allergic inflammation and asthma regarding both biological and genetic point of view. Recent findingsRegarding eosinophils, the role of interleukin ( SummaryRecent findings from biological and genetic studies on eosinophils and basophils highlight the role of epithelial cell-derived cytokines such as TSLP and IL-33 in asthma and allergic diseases.

show abstract

“…Inflammatory cells such as eosinophils and neutrophils participate in tissue injury through the release of cytotoxic products and formation of reactive oxidant species (1)(2)(3)(4)(5)(6). Some of the most abundant proteins in them are their respective heme-dependent peroxidases, eosinophil peroxidase (EPO), 3 and myeloperoxidase (MPO).…”

mentioning

confidence: 99%